After three years of wealth-destroying losses, this S&P 500 stock's suddenly roared back into life in our writer's SIPP. What ...

The strategy carries risks, because support for Kennedy is cratering and polls show voters care more about reducing health ...

Two of the vaccines we have for COVID-19 have the distinction of being the first mRNA vaccines to see widespread use in ...

Dr. Robert Malone — a member of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices ...

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

YieldMax MRNA Option Income Strategy ETF's distributions have increased alongside MRNA's share price resurgence. See more on MRNY ETF here.

Melanoma, known for its aggressiveness and high mutational burden, presents itself as a prime candidate for neoantigen-targeted immunotherapies. Although ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer ...

Moderna does not plan to ‌invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S.